



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 4, 2022

John Moriarty
Chief Legal Officer
Olema Pharmaceuticals, Inc.
512 2nd Street, 4th Floor
San Francisco, California 94107

Re: Olema Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed March 1, 2022
File No. 333-263117

Dear Mr. Moriarty:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jessica Ansart at (202) 551-4511 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Jodie Bourdet